rdf:type |
|
lifeskim:mentions |
umls-concept:C0010294,
umls-concept:C0011860,
umls-concept:C0019878,
umls-concept:C0023822,
umls-concept:C0030705,
umls-concept:C0033228,
umls-concept:C0085201,
umls-concept:C0085202,
umls-concept:C0332293,
umls-concept:C0332307,
umls-concept:C0439849
|
pubmed:issue |
6
|
pubmed:dateCreated |
2009-5-21
|
pubmed:abstractText |
The purpose of this study was to determine fenofibrate-induced changes in plasma high-density lipoprotein cholesterol (HDL-C), apolipoprotein (apo) A-I, and apolipoprotein (apo) A-II and how they relate to changes in plasma homocysteine and creatinine.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/APOA1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/APOA2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoprotein A-I,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoprotein A-II,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Fenofibrate,
http://linkedlifedata.com/resource/pubmed/chemical/Homocysteine,
http://linkedlifedata.com/resource/pubmed/chemical/Hypolipidemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/PPAR alpha
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1524-4636
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
950-5
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:19325138-Apolipoprotein A-I,
pubmed-meshheading:19325138-Apolipoprotein A-II,
pubmed-meshheading:19325138-Australia,
pubmed-meshheading:19325138-Biological Markers,
pubmed-meshheading:19325138-Cholesterol, HDL,
pubmed-meshheading:19325138-Creatinine,
pubmed-meshheading:19325138-Diabetes Mellitus, Type 2,
pubmed-meshheading:19325138-Double-Blind Method,
pubmed-meshheading:19325138-Dyslipidemias,
pubmed-meshheading:19325138-Fenofibrate,
pubmed-meshheading:19325138-Finland,
pubmed-meshheading:19325138-Homocysteine,
pubmed-meshheading:19325138-Humans,
pubmed-meshheading:19325138-Hypolipidemic Agents,
pubmed-meshheading:19325138-New Zealand,
pubmed-meshheading:19325138-PPAR alpha,
pubmed-meshheading:19325138-Treatment Outcome
|
pubmed:year |
2009
|
pubmed:articleTitle |
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
|
pubmed:affiliation |
Department of Medicine, Division of Cardiology, Helsinki University Hospital, Biomedicum, Haartmaninkatu 8, 00029 Helsinki, Finland. Marja-Riitta.Taskinen@helsinki.fi
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|